Novartis India Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here
Posted by : sachet | Tue Jan 27 2026
Click and Sign Up to Get Live Updates on Q3 Results
Novartis India’s Q3 results FY26 are scheduled to be announced on 28th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Novartis India Q3 Results 2026 Preview
- Novartis India’s revenue is expected to be in the range of ₹93.00 crore, a 6.77% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 24.69% YoY.
- Novartis India’s EBITDA is expected to rise to ₹25.05 crore.
- Net profit is ₹25.45 crore, a rise of 24.69% YoY
Novartis India Share Performance
- Over the past six months, Novartis India’s share price has fallen by 19.09% to ₹804.00.
- Moreover, over the past year, the stock has decreased by 11.02%.
- Despite this weak short-term performance, Novartis India’s stock has delivered a financially sound 22.83% return over the past 5 years.
- As of 27th January 2026, the stock traded at ₹804.00 per share.
Key Factors to Watch for Novartis India Q3 Results FY26
- Revenue & sales trends – Movement in topline, including growth or contraction in domestic pharma sales against a backdrop of patent expiries and pricing pressures.
- Profitability & margins – Net profit and operating margin trends, especially in light of margin compression seen in recent quarters.
- Product mix & new launches – Performance of key branded drugs and impact of new product introductions on growth.
- Cost & receivables management – Efficiency in working capital and receivables (e.g., turnover ratios) that affect cash flows.
- Strategic initiatives/stake review developments – Impact of any strategic review or structural changes in the listed India entity that may influence investor sentiment.
Final Thoughts
Novartis India will announce its Q3 FY26 results on 28th January 2026. Analysts expect 6.77% YoY revenue growth, a 24.69% rise in PAT, and a 44.13% rise in EBITDA. Novartis India focuses on sustaining modest revenue growth amid pricing and competitive pressures while protecting margins and leveraging new or high‑value product portfolios to drive earnings.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Novartis Indiaelerator IPO GMP & Review: Apply or Avoid?
Related Posts
Maharashtra Seamless Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here
Heritage Foods Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here
CSB Bank Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here
Cochin Shipyard Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here
Atul Q3 Results 2026 Highlights: Net Profit Surged by 47.82% & Revenue Up 11.07% YoY
